Authors: Chlebowski, RT

Citation: Rt. Chlebowski, Factors influencing the role of bisphosphonates in breast cancer management, SEMIN ONCOL, 28(4), 2001, pp. 42-48

Authors: Lam, RY Chlebowski, RT

Citation: Ry. Lam et Rt. Chlebowski, Tamoxifen for treatment of premenopausal women with breast cancer, CANCER INV, 18(7), 2000, pp. 681-684

Authors: Hillner, BE Ingle, JN Berenson, JR Janjan, NA Albain, KS Lipton, A Yee, G Biermann, JS Chlebowski, RT Pfister, DG

Citation: Be. Hillner et al., American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer, J CL ONCOL, 18(6), 2000, pp. 1378-1391

Authors: Chlebowski, RT

Citation: Rt. Chlebowski, Primary care: Reducing the risk of breast cancer, N ENG J MED, 343(3), 2000, pp. 191-198

Authors: Chlebowski, RT Collyar, DE Somerfield, MR Pfister, DG

Citation: Rt. Chlebowski et al., American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene, J CL ONCOL, 17(6), 1999, pp. 1939-1955

Authors: Chlebowski, RT McTiernan, A

Citation: Rt. Chlebowski et A. Mctiernan, Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer, J CL ONCOL, 17(1), 1999, pp. 130-142